Off-Label Use of Biologics and JAK Inhibitors in Dermatology

The presentation focuses on the off-label use of biologics and JAK inhibitors in dermatology, particularly highlighting innovative treatments for conditions like hidradenitis suppurativa (HS) and cutaneous lupus. It emphasizes the importance of optimizing approved therapies rather than solely relying on them as-is, especially noting the potential for higher dosing in response to patient-specific factors such as body mass index (BMI). The speaker discusses FDA-approved treatments currently available for HS, such as adalimumab and secukinumab, and introduces the benefits of emerging therapies like vimikizumab and anifrolumab for recalcitrant cases. Anifrolumab is particularly recommended for cutaneous lupus due to its promising efficacy in reducing disease activity and improving skin conditions. The discussion also reflects on the potential of topical JAK inhibitors like rexaltinib in treating various dermatological diseases. Overall, the talk underscores the transformative advancements in dermatologic therapeutics, encouraging healthcare providers to utilize these strategies in patient care.